(Q33680252)

English

Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients

scientific article

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients (English)

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

0 references

1 reference

based on heuristic

inferred from title

10

object named as

David Dingli

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Angela Dispenzieri

7

object named as

Angela Dispenzieri

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

18

object named as

Robert A Kyle

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

3

object named as

Martha Q Lacy

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Stephen J. Russell

13

object named as

Stephen J Russell

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

S. Vincent Rajkumar

21

object named as

S Vincent Rajkumar

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

5

object named as

Morie A Gertz

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Suzanne R Hayman

2

object named as

Suzanne R Hayman

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Steven R Zeldenrust

15

object named as

Steven R Zeldenrust

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

12

object named as

John A Lust

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Francis K Buadi

4

object named as

Francis Buadi

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

6

object named as

Shaji Kumar

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Thomas E. Witzig

16

object named as

Thomas E Witzig

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

P Leif Bergsagel

9

object named as

P Leif Bergsagel

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

11

object named as

Craig B Reeder

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

14

object named as

Vivek Roy

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

8

object named as

Joseph R Mikhael

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Philip R. Greipp

19

object named as

Philip R Greipp

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

1

object named as

Francesca Gay

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

object named as

Rafael Fonseca

17

0 references

author name string

A Keith Stewart

20

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

language of work or name

0 references

publication date

11 December 2009

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

number of pages

8

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

115

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

1343-1350

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2826759

21 June 2018

Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2826759

21 June 2018

Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2826759

21 June 2018

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2826759

21 June 2018

Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2826759

21 June 2018

Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2826759

21 June 2018

Multiple myeloma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2826759

21 June 2018

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2826759

21 June 2018

VAD-based regimens as primary treatment for multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2826759

21 June 2018

Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2826759

30 October 2018

Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2826759

30 October 2018

Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2826759

30 October 2018

Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2826759

30 October 2018

Multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20008302

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1182/BLOOD-2009-08-239046

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33680252&oldid=1902758436"